We have previously shown that human melanoma xenografts expressing moderate levels of MGMT do respond to growth inhibition by temozolomide, but this is considerably enhanced by pretreatment with PaTrin-2 (Middleton et al, 2000, 2002). This evidence concerns the gene MGMT and melanoma.